Laurus Labs Limited delivered a record financial performance in the first quarter of FY27, with strong execution across its contract development and manufacturing (CDMO) business driving both revenue growth and margin expansion. The company reported revenue of ₹2,026 crore, up 29% year-on-year, while EBITDA rose 66% to ₹644 crore, reflecting improved operating efficiency and a favourable product mix.

A key highlight of the quarter was the exceptional performance of the CDMO business, which has become an increasingly important growth engine for Laurus Labs. CDMO revenue surged 67% year-on-year to ₹870 crore, supported by higher commercial manufacturing activity and supplies for late-stage clinical programmes. Within this segment, Small Molecules CDMO revenue climbed 69% to ₹835 crore, while Bio CDMO revenue increased 21% to ₹35 crore.

The Affordable Medicines business also remained resilient, with revenue rising 10% year-on-year to ₹1,156 crore. The growth was supported by stable demand for antiretroviral (ARV) products and the launch of new products in the US market. The combination of a strong CDMO contribution and stable base business helped diversify revenue streams during the quarter.

Profitability improved significantly across key metrics. Gross margin expanded by more than 300 basis points to 62.7%, while EBITDA margin improved by around 700 basis points to 31.8%. According to management, the improvement was driven by a more favourable business mix, better capacity utilisation and operating leverage as higher-value manufacturing contributed a larger share of revenue.

Beyond quarterly financial performance, Laurus Labs continued to invest in future growth. The company signed agreements to in-license two Antibody Drug Conjugates (ADCs), strengthening its presence in advanced oncology therapeutics. ADCs are among the fastest-growing segments in innovative pharmaceuticals, and the agreements indicate the company's intent to build differentiated capabilities beyond traditional generic manufacturing.

The company also secured a new land parcel to support long-term expansion and confirmed that its capital expenditure programme remains on schedule. Investments continue across multiple platforms including Small Molecules, Fermentation, Peptides, Gene Therapy and ADC manufacturing. Management indicated that the new fermentation facility is expected to be commissioned during Q3 FY27, adding capacity for future commercial opportunities.

On the regulatory front, Laurus Labs continued expanding its global product pipeline by filing two new developed-market finished dosage formulation (FDF) dossiers during the quarter. This increased cumulative FDF filings to 96 products, while cumulative Drug Master File (DMF) filings reached 92. These filings enhance future product launch opportunities across regulated markets and support the company's long-term growth strategy.

Management also highlighted efforts to deepen client relationships by strengthening integrated development and manufacturing capabilities. The strategy reflects a broader industry trend where pharmaceutical companies increasingly seek end-to-end manufacturing partners capable of supporting products from clinical development through commercial production.

Market Impact on India

The strong quarterly performance reinforces confidence in India's pharmaceutical manufacturing sector, particularly in high-value CDMO services where global outsourcing demand continues to rise. Continued investment in advanced therapies also strengthens India's position in specialised pharmaceutical manufacturing.

Sector Impact

The results are positive for the healthcare and pharmaceutical sectors, particularly companies with exposure to CDMO and regulated export markets. Margin expansion driven by better product mix highlights the earnings potential of shifting toward complex manufacturing and specialty products.

Bull vs Bear Scenario

The bullish case is that sustained CDMO momentum, higher-margin product mix and ongoing capacity additions could support multi-year earnings growth. Expansion into ADCs and advanced biologics also creates new long-term growth avenues.

The bearish scenario is that CDMO revenues can remain project-driven and may fluctuate depending on customer timelines. Delays in commissioning new facilities or slower commercialisation of new therapies could moderate future growth.

Risk Section

Key risks include execution delays in capex projects, regulatory approvals for new facilities, customer concentration in CDMO contracts and pricing pressure in export markets. Currency fluctuations and changes in global pharmaceutical procurement patterns may also influence future earnings.

Overall, Laurus Labs delivered one of its strongest quarterly performances, combining robust revenue growth with substantial margin expansion while continuing to invest in advanced manufacturing capabilities and long-term product development.